Plain-English translation of NCT07386158 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications—Pucotenlimab and Vorolanib—given together before surgery can shrink kidney tumors and make it possible to remove just the cancer while preserving more healthy kidney tissue. You would receive this medication combination for up to 4 cycles before having surgery to remove the tumor.
Some kidney cancers are large or located in difficult spots that make it very hard for surgeons to remove the tumor while saving kidney function. This trial explores whether shrinking the tumor first with medication can make the surgery safer and help preserve more of your kidney.
You likely qualify if…
You likely don't qualify if…
You would take Vorolanib as a daily oral pill and receive intravenous infusions of Pucotenlimab every three weeks for up to 4 treatment cycles. After 2 cycles, you would have imaging scans to check if the tumor is shrinking. If it shrinks enough and your surgeon believes the tumor can be safely removed while preserving your kidney, you would stop medication and proceed to surgery. The entire process from starting medication to surgery would likely take several months.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China